Ishita Drugs & Industries Ltd
Incorporated in 1992, Ishita Drugs & Industries
Ltd is engaged in the manufacturing of various APIs and drug intermediates[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Purchased KWH ・Standalone data |
|
|||||||||
| Foreign Exchange Earnings (Exports) INR ・Standalone data |
||||||||||
| Imported Raw Material Share % of total raw material consumed ・Standalone data |
||||||||||
| Permanent Employees on Rolls persons ・Standalone data |
||||||||||
| R&D Expenditure INR ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Closure of Trading Window
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Availing Credit Facilities From Bank
- Entered 11.75 crore loan agreement with HDFC Bank on 22.09.2026 for Sanand facility upgradation.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 22Nd September, 2026
- Board approved Rs 11.75 crore borrowing from HDFC Bank on 22 September 2026.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015
- Board meeting on 22 Sept 2026 to consider raising working capital and project term loans.
-
Weblink Intimation Letter To The Shareholders
- 33rd AGM scheduled for 30 September 2026; annual report and notice web link shared with shareholders.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2]
IDIL is a flagship company of Ishita
Group. It is in the business of manufacturing
and sale of Bulk Drugs, Fine Chemicals, and Intermediates. The company supplies
its products to pharmaceutical companies
in India and abroad